Literature DB >> 24077889

Depressive syndromes in neurological disorders.

Julian Hellmann-Regen, Dominique Piber, Kim Hinkelmann, Stefan M Gold, Christoph Heesen, Carsten Spitzer, Matthias Endres, Christian Otte.   

Abstract

Depressive syndromes represent a common and often characteristic feature in a number of neurological disorders. One prominent example is the development of post-stroke depression, which can be observed in more than one-third of stroke survivors in the aftermath of an ischemic stroke. Thus, post-stroke depression represents one of the most prevalent, disabling, and potentially devastating psychiatric post-stroke complications. On the other hand, depressive syndromes may also be considered as a risk factor for certain neurological disorders, as recently revealed by a meta-analysis of prospective cohort studies, which demonstrated an increased risk for ischemic events in depressed patients. Moreover, depressive syndromes represent common comorbidities in a number of other neurological disorders such as Parkinson's disease, multiple sclerosis, or epilepsy, in which depression has a strong impact on both quality of life and outcome of the primary neurological disorder.

Entities:  

Mesh:

Year:  2013        PMID: 24077889     DOI: 10.1007/s00406-013-0448-6

Source DB:  PubMed          Journal:  Eur Arch Psychiatry Clin Neurosci        ISSN: 0940-1334            Impact factor:   5.270


  161 in total

1.  Cognitive-behavioral therapy for depression in Parkinson's disease: a pilot study.

Authors:  Roseanne DeFronzo Dobkin; Lesley A Allen; Matthew Menza
Journal:  Mov Disord       Date:  2007-05-15       Impact factor: 10.338

2.  Telephone-administered psychotherapy for depression.

Authors:  David C Mohr; Stacey L Hart; Laura Julian; Claudine Catledge; Lara Honos-Webb; Lea Vella; Edwin T Tasch
Journal:  Arch Gen Psychiatry       Date:  2005-09

3.  Guidelines for the primary prevention of stroke: a guideline for healthcare professionals from the American Heart Association/American Stroke Association.

Authors:  Larry B Goldstein; Cheryl D Bushnell; Robert J Adams; Lawrence J Appel; Lynne T Braun; Seemant Chaturvedi; Mark A Creager; Antonio Culebras; Robert H Eckel; Robert G Hart; Judith A Hinchey; Virginia J Howard; Edward C Jauch; Steven R Levine; James F Meschia; Wesley S Moore; J V Ian Nixon; Thomas A Pearson
Journal:  Stroke       Date:  2010-12-02       Impact factor: 7.914

4.  Risk factors for suicide in multiple sclerosis.

Authors:  E N Stenager; N Koch-Henriksen; E Stenager
Journal:  Psychother Psychosom       Date:  1996 Mar-Apr       Impact factor: 17.659

5.  Distance delivery of mindfulness-based cognitive therapy for depression: project UPLIFT.

Authors:  Nancy J Thompson; Elizabeth Reisinger Walker; Natasha Obolensky; Ashley Winning; Christina Barmon; Colleen Diiorio; Michael T Compton
Journal:  Epilepsy Behav       Date:  2010-09-20       Impact factor: 2.937

6.  [Dementia and depression determine care dependency in Parkinson's disease: analysis of 1,449 outpatients receiving nursing care in Germany].

Authors:  O Riedel; R Dodel; G Deuschl; H Förstl; F Henn; I Heuser; W Oertel; H Reichmann; P Riederer; C Trenkwalder; H U Wittchen
Journal:  Nervenarzt       Date:  2011-08       Impact factor: 1.214

7.  An examination of suicidal intent in patients with multiple sclerosis.

Authors:  Anthony Feinstein
Journal:  Neurology       Date:  2002-09-10       Impact factor: 9.910

Review 8.  Safety and efficacy of psychopharmacological agents used to treat the psychiatric sequelae of common neurological disorders.

Authors:  Carmina G Bernardo; Vivek Singh; Peter M Thompson
Journal:  Expert Opin Drug Saf       Date:  2008-07       Impact factor: 4.250

9.  Impact of fluoxetine on the human brain in multiple sclerosis as quantified by proton magnetic resonance spectroscopy and diffusion tensor imaging.

Authors:  Paul E Sijens; Jop P Mostert; Roy Irwan; Jan Hendrik Potze; Matthijs Oudkerk; Jacques De Keyser
Journal:  Psychiatry Res       Date:  2008-12-30       Impact factor: 3.222

10.  Depressive symptoms and smoking cessation after hospitalization for cardiovascular disease.

Authors:  Anne N Thorndike; Susan Regan; Kathleen McKool; Richard C Pasternak; Susan Swartz; Nancy Torres-Finnerty; Nancy A Rigotti
Journal:  Arch Intern Med       Date:  2008-01-28
View more
  16 in total

1.  Selected topics of the DGPPN Congress 2012.

Authors:  Andrea Schmitt; Peter Falkai
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  2013-11       Impact factor: 5.270

2.  Depression and cognitive impairment following recovery from thrombotic thrombocytopenic purpura.

Authors:  Bowie Han; Evaren E Page; Lauren M Stewart; Cassandra C Deford; James G Scott; Lauren H Schwartz; Jedidiah J Perdue; Deirdra R Terrell; Sara K Vesely; James N George
Journal:  Am J Hematol       Date:  2015-05-28       Impact factor: 10.047

Review 3.  Effects of music and music therapy on mood in neurological patients.

Authors:  Alfredo Raglio; Lapo Attardo; Giulia Gontero; Silvia Rollino; Elisabetta Groppo; Enrico Granieri
Journal:  World J Psychiatry       Date:  2015-03-22

Review 4.  Purinergic system dysfunction in mood disorders: a key target for developing improved therapeutics.

Authors:  Robin Ortiz; Henning Ulrich; Carlos A Zarate; Rodrigo Machado-Vieira
Journal:  Prog Neuropsychopharmacol Biol Psychiatry       Date:  2014-11-07       Impact factor: 5.067

Review 5.  Glutamate Efflux across the Blood-Brain Barrier: New Perspectives on the Relationship between Depression and the Glutamatergic System.

Authors:  Benjamin Fredrick Gruenbaum; Alexander Zlotnik; Amit Frenkel; Ilya Fleidervish; Matthew Boyko
Journal:  Metabolites       Date:  2022-05-20

Review 6.  New framework for rehabilitation - fusion of cognitive and physical rehabilitation: the hope for dancing.

Authors:  Prabhjot Dhami; Sylvain Moreno; Joseph F X DeSouza
Journal:  Front Psychol       Date:  2015-01-28

7.  The Association Between C424c/A Polymorphism Within the IL-25 Gene and Multiple Sclerosis.

Authors:  Lida Zare; Mahmood Sheikh Fathollahi; Mohammad Kazemi Arababadi; Ali Shamsizadeh; Behnam Daneshpajouh; Nahid Zainodini; Mohammad Allahtavakoli
Journal:  Iran Red Crescent Med J       Date:  2016-02-20       Impact factor: 0.611

8.  Post-marketing observational program of the effectiveness of fluvoxamine for the treatment of depression in patients with neurological disorders: the FRIENDS study.

Authors:  Nikolay N Yahno; Anastasia V Fedotova
Journal:  Neuropsychiatr Dis Treat       Date:  2017-11-02       Impact factor: 2.570

9.  Anxiety and depression mediate the health-related quality of life differently in patients with cardiovascular disease and stroke-preliminary report of the Yilan study: a population-based community health survey.

Authors:  Nai-Wei Hsu; Hsuan-Ming Tsao; Hsi-Chung Chen; Pesus Chou
Journal:  PLoS One       Date:  2014-09-16       Impact factor: 3.240

10.  Human ventromedial prefrontal lesions alter incentivisation by reward.

Authors:  Sanjay G Manohar; Masud Husain
Journal:  Cortex       Date:  2016-01-19       Impact factor: 4.027

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.